Shares of ProMetic Life Sciences Inc. (TSE:PLI) hit a new 52-week low during trading on Monday . The stock traded as low as C$0.40 and last traded at C$0.40, with a volume of 797331 shares. The stock had previously closed at C$0.43.
Separately, TD Securities lowered shares of ProMetic Life Sciences from a “speculative buy” rating to a “hold” rating and lowered their price objective for the stock from C$2.00 to C$1.00 in a report on Friday, August 17th.
ProMetic Life Sciences (TSE:PLI) last released its earnings results on Tuesday, August 14th. The company reported C($0.05) earnings per share (EPS) for the quarter. The firm had revenue of C$20.16 million for the quarter, compared to analysts’ expectations of C$5.50 million.
About ProMetic Life Sciences (TSE:PLI)
ProMetic Life Sciences Inc, a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. It operates through three segments: Small-Molecule Therapeutics, Plasma-Derived Therapeutics, and Bioseparation Technologies. The company offers its technology platform for purification of biologics, drug development, proteomics, and elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, inflammation, autoimmune diseases, oncology, and nephropathies.
Further Reading: What does cost of debt say about a company’s financial health?
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.